A randomized, double-blind, parallel, single dose comparative pharmacokinetic study of Zydus Adalimumab (ZRC-3197) Injection and HUMIRAÂ® Adalimumab Injection in healthy adult human subjects.

Cadila Healthcare Ltd0 个研究点目标入组 154 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1)BMI:18.5 to 30.0 weight in kg/(height in meter)2 both inclusive; BMI value should be rounded off to one significant digit after decimal point (e.g. 30.04 rounds down to 30.0, while 18.45 rounds up to 18.5).
•2)Volunteer having body weight between 50 to 85 Kg (both inclusive).
•3)Non-smokers and non-tobacco users (i.e. having no past history of smoking and tobacco consuming for at least one year prior to study).
•4)Able to communicate effectively with study personnel.
•5)Able to give written informed consent to participate in the study.
•6)Able to signed and dated written informed consent prior to any study-specific procedures, Willing and able to comply with the study procedures, restrictions and requirements.
•7)Volunteers who are negative for drugs of abuse and alcohol breath tests at screening.
•8)Male Volunteers should be willing to use a condom (with spermicide) to prevent pregnancy and drug exposure of a female partner and refrain from donating sperm or fathering a child during the course of the study and 03 months after administration of study medication.

•1)History of allergic responses/exposure to Adalimumab or HUMIRA or other related drugs, or antibodies.
•2)Have significant diseases or clinically significant abnormal findings during screening [medical history, physical examination, laboratory evaluations, ECG, chest X-ray recording, obstetrics and gynecological history and examination along (for female volunteers)].
•3)Any disease or condition like diabetes, psychosis or others which might compromise the haemopoeitic, gastrointestinal, renal, hepatic, cardiovascular, ophthalmic, pulmonary, metabolic, endocrine, immunological, respiratory, central nervous system or any other body system.
•4)History or presence of bronchial asthma.
•5)Use of any hormone replacement therapy within 3 months prior to the study medication.
•6)A depot injection or implant of any drug within 3 months prior to the study medication.
•7)Use of enzyme-modifying drugs within 30 days prior to the study medication.
•8)History of drug dependence or of alcoholism or of moderate alcohol use
•9)History of difficulty with donating blood or difficulty in accessibility of veins.
•10)A positive hepatitis screen (includes subtypes B & C).
•11)A positive test result for HIV antibody and / or syphilis (RPR/VDRL).

发起方